Emergent BioSolutions Inc 8-K, filed Oct 4, 2024
Emergent BioSolutions Inc. (EBS)
8-K
2024-10-04
For: 2024-10-02
View Original
Added on
April 01, 2026
About this 8-K
Emergent BioSolutions Inc filed this 8-K on October 4, 2024, reporting on events of October 2, 2024.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2024
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of incorporation) | Identification No.) | |||||||||||||
(Address of principal executive offices, including zip code)
(240 ) 631-3200
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) On October 2, 2024, the Compensation Committee of the Board of Directors of Emergent BioSolutions Inc. (the “Company”), approved a special one-time discretionary equity award to be granted to Richard S. Lindahl, the Company’s Executive Vice President, Chief Financial Officer and Treasurer of 15,000 restricted stock units, which will have a grant date of October 15, 2024 and will vest on the first anniversary of the date of grant (the “Award”). The Award is subject to Mr. Lindahl's continued employment with the Company through the applicable vesting date, the terms and conditions of the Company’s Amended and Restated Stock Incentive Plan, Global Restricted Stock Unit Award Agreement, and Second Amended and Restated Senior Management Severance Plan. This Award is in recognition of Mr. Lindahl’s substantial contributions in executing recent strategic initiatives.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EMERGENT BIOSOLUTIONS INC. | ||||||||
| Dated: October 4, 2024 | By: | /s/ Jessica Perl | ||||||
| Name: Jessica Perl Title: VP, Corporate Secretary and Interim General Counsel | ||||||||